Want to see GANX full AI Analyst Report?
Top Page
Gain Therapeutics
(NASDAQ:GANX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-6.10% Downside)
Action:Reiterated
Date:06/30/26
The score is primarily constrained by weak financial performance (pre-revenue, large ongoing losses and cash burn), partially offset by low balance-sheet leverage. Corporate developments are a positive catalyst (IND clearance and supportive interim clinical/biomarker updates), but limited technical data and a loss-driven negative P/E provide little additional support.
Positive Factors
Regulatory milestone (IND clearance)
IND clearance for GT-02287 establishes a clear regulatory path to U.S. Phase 2, validating preclinical and early clinical work. This materially de-risks program progression, enables multi-region enrollment, and strengthens the company’s ability to attract partners and non-dilutive financing over the medium term.
Negative Factors
High cash burn
Sustained negative operating and free cash flow indicate material cash burn that must be financed externally. Persistent outflows constrain runway, raise dilution risk, and could force hurried financings that reduce strategic optionality during critical Phase 2 execution and readout periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory milestone (IND clearance)
IND clearance for GT-02287 establishes a clear regulatory path to U.S. Phase 2, validating preclinical and early clinical work. This materially de-risks program progression, enables multi-region enrollment, and strengthens the company’s ability to attract partners and non-dilutive financing over the medium term.
Read all positive factors
Gain Therapeutics (GANX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.59M
Dividend YieldN/A
Average Volume (3M)633.19K
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue GrowthN/A
EPS Growth33.86%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding42,654,037
10 Day Avg. Volume577,029
30 Day Avg. Volume633,186
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.97
Forecast
1Y Price Target
$7.20Price Target Upside238.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.56
Revenue Forecast (FY)N/A
Gain Therapeutics Business Overview & Revenue Model
Company Description
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurologic...
How the Company Makes Money
null...
Gain Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 55.18K | 140.11K | 164.99K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 55.18K | 140.11K | 164.99K |
| EBITDA | -20.20M | -19.21M | -19.79M | -22.10M | -17.43M | -13.87M |
| Net Income | -21.24M | -20.16M | -20.41M | -22.27M | -17.59M | -13.89M |
Balance Sheet | ||||||
| Total Assets | 18.74M | 22.82M | 12.12M | 18.61M | 24.10M | 38.99M |
| Cash, Cash Equivalents and Short-Term Investments | 16.54M | 20.84M | 10.39M | 16.79M | 20.14M | 36.88M |
| Total Debt | 672.30K | 732.07K | 653.01K | 1.03M | 1.27M | 1.61M |
| Total Liabilities | 4.73M | 4.25M | 4.78M | 6.03M | 5.22M | 4.17M |
| Stockholders Equity | 14.01M | 18.56M | 7.34M | 12.58M | 18.88M | 34.82M |
Cash Flow | ||||||
| Free Cash Flow | -19.37M | -18.47M | -18.90M | -18.88M | -14.81M | -12.46M |
| Operating Cash Flow | -19.37M | -18.47M | -18.87M | -18.87M | -14.69M | -12.37M |
| Investing Cash Flow | 0.00 | 0.00 | 4.98M | 10.22M | -14.77M | -94.21K |
| Financing Cash Flow | 26.46M | 28.45M | 13.01M | 12.64M | -78.77K | 41.77M |
Gain Therapeutics Technical Analysis
Positive
2.13
Price Trends
1.83
Positive
1.98
Positive
2.20
Negative
Market Momentum
-0.02
Negative
47.60
Neutral
30.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GANX, the sentiment is Positive. The current price of 2.13 is above the 20-day moving average (MA) of 1.78, above the 50-day MA of 1.83, and below the 200-day MA of 2.20, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.60 is Neutral, neither overbought nor oversold. The STOCH value of 30.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GANX.
Gain Therapeutics Risk Analysis
Gain Therapeutics disclosed 9 risk factors in its most recent earnings report. Gain Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gain Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $86.59M | -3.47 | -201.43% | ― | ― | 33.86% | |
46 Neutral | $41.08M | -13.84 | -92.03% | ― | -100.00% | -170.04% | |
45 Neutral | $71.46M | -0.89 | -68.98% | ― | ― | -26.14% | |
44 Neutral | $30.08M | -0.01 | -198.48% | ― | -0.46% | 96.28% | |
44 Neutral | $424.51M | -5.09 | -118.24% | ― | 138.86% | 42.14% |
* Healthcare Sector Average
GANX
Gain Therapeutics
2.03
0.46
29.30%
PSTV
Plus Therapeutics
4.37
-3.38
-43.63%
ABVC
ABVC BioPharma
1.58
-0.84
-34.71%
PMVP
PMV Pharmaceuticals
1.34
0.29
27.62%
PRLD
Prelude Therapeutics
5.33
4.53
566.25%
IMMX
Immix Biopharma
10.31
8.12
370.78%
Gain Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
Positive
Jun 29, 2026
On June 29, 2026, Gain Therapeutics said the U.S. Food and Drug Administration had cleared its Investigational New Drug application for GT-02287, enabling the launch of Phase 2 clinical development in Parkinson’s disease patients with or wit...
Executive/Board ChangesShareholder Meetings
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
Positive
Jun 25, 2026
On June 24, 2026, Gain Therapeutics, Inc. held its annual meeting of stockholders, where shareholders elected seven directors, including Gene Mack and Dov Goldstein, M.D., to serve one-year terms until their successors are duly chosen. The vote to...
Business Operations and StrategyProduct-Related Announcements
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
Positive
May 26, 2026
On May 26, 2026, Gain Therapeutics reported interim clinical and biomarker data from the nine‑month extension (Part 2) of its Phase 1b open‑label study of GT‑02287 in Parkinson’s disease patients, following an oral presenta...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.